Literature DB >> 11430710

Insulin improves clinical status of patients with cystic-fibrosis-related diabetes mellitus.

S Nousia-Arvanitakis1, A Galli-Tsinopoulou, M Karamouzis.   

Abstract

UNLABELLED: Cystic-fibrosis-related diabetes mellitus is frequently underdiagnosed and associated with deterioration of overall clinical status. The purpose of this prospective study was to investigate the influence of insulin on nutrition, lung function and clinical status of cystic fibrosis patients. For a period of 5 y, and at 6-mo intervals, body mass index, forced expiratory volume in 1 sec, Shwachman score, intravenous glucose tolerance test and first-phase insulin response were determined in 30 cystic fibrosis patients (age range 10-35 y) with exocrine pancreatic insufficiency. During the study period, six patients (3M and 3F; age range 15-22 y) developed diabetes and required insulin therapy. The decrease of first-phase insulin response coincided with deterioration of nutritional and clinical status, which improved significantly 6 mo after the institution of insulin.
CONCLUSION: Insulin, as an anabolic hormone, could have an influence on body mass, which may affect pulmonary function and clinical condition in cystic fibrosis. It is important to identify cystic fibrosis individuals at risk of developing diabetes so that early insulin therapy is instituted.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11430710

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  16 in total

Review 1.  Understanding cystic-fibrosis-related diabetes: best thought of as insulin deficiency?

Authors:  Lee Dobson; Christopher D Sheldon; Andrew T Hattersley
Journal:  J R Soc Med       Date:  2004       Impact factor: 5.344

Review 2.  Routine screening for cystic fibrosis-related diabetes.

Authors:  Daniel Peckham
Journal:  J R Soc Med       Date:  2009-07       Impact factor: 5.344

3.  Clinical effects of early treatment with insulin glargine in patients with cystic fibrosis and impaired glucose tolerance.

Authors:  C Bizzarri; V Lucidi; P Ciampalini; S Bella; B Russo; M Cappa
Journal:  J Endocrinol Invest       Date:  2006-03       Impact factor: 4.256

4.  Oral glucose tolerance testing in children with cystic fibrosis.

Authors:  Katie Larson Ode; Brigitte Frohnert; Theresa Laguna; James Phillips; Bonnie Holme; Warren Regelmann; William Thomas; Antoinette Moran
Journal:  Pediatr Diabetes       Date:  2010-11       Impact factor: 4.866

5.  Cystic fibrosis-related diabetes: from CFTR dysfunction to oxidative stress.

Authors:  Thierry Ntimbane; Blandine Comte; Geneviève Mailhot; Yves Berthiaume; Vincent Poitout; Marc Prentki; Rémi Rabasa-Lhoret; Emile Levy
Journal:  Clin Biochem Rev       Date:  2009-11

6.  Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial.

Authors:  Antoinette Moran; Penelope Pekow; Patricia Grover; Martha Zorn; Bonnie Slovis; Joseph Pilewski; Elizabeth Tullis; Theodore G Liou; Holley Allen
Journal:  Diabetes Care       Date:  2009-07-10       Impact factor: 17.152

Review 7.  Epidemiology, pathophysiology, and prognostic implications of cystic fibrosis-related diabetes: a technical review.

Authors:  Antoinette Moran; Dorothy Becker; Samuel J Casella; Peter A Gottlieb; M Sue Kirkman; Bruce C Marshall; Bonnie Slovis
Journal:  Diabetes Care       Date:  2010-12       Impact factor: 19.112

Review 8.  Diagnosis and treatment of endocrine comorbidities in patients with cystic fibrosis.

Authors:  Oranan Siwamogsatham; Jessica A Alvarez; Vin Tangpricha
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2014-10       Impact factor: 3.243

9.  Genetic modifiers play a substantial role in diabetes complicating cystic fibrosis.

Authors:  Scott M Blackman; Stephanie Hsu; Lori L Vanscoy; J Michael Collaco; Sarah E Ritter; Kathleen Naughton; Garry R Cutting
Journal:  J Clin Endocrinol Metab       Date:  2009-01-06       Impact factor: 5.958

10.  Diabetes outbreak during COVID19 lock-down in a prediabetic patient with cystic fibrosis long treated with glargine.

Authors:  Francesco Maria Rosanio; Enza Mozzillo; Chiara Cimbalo; Alberto Casertano; Angela Sepe; Valeria Raia; Adriana Franzese; Antonella Tosco
Journal:  Ital J Pediatr       Date:  2021-06-02       Impact factor: 2.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.